Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: A systematic review

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Egunsola, Oluwaseun ^a   Oshikoya, Kazeem A ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LAGOS STATE UNIVERSITY   (Nigeria)

Author keywords

Adverse event; Artemether lumefantrine; Children; Paediatrics; Safety

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS AZITHROMYCIN; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTHRALGIA; CHILDHOOD DISEASE; COCHRANE LIBRARY; COMMON COLD; COMPARATIVE STUDY; CONVULSION; COUGHING; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EMBASE; FATIGUE; HEART PALPITATION; HEMOLYSIS; HEPATOMEGALY; HUMAN; INSOMNIA; JAUNDICE; MALARIA; MEDLINE; MOUTH ULCER; NEUTROPENIA; NYSTAGMUS; PAIN; PRURITUS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADOLESCENT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COUGH; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DYSPEPSIA; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886743846     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-385     Document Type: Review

References (53)

1. World Health Organization, Malaria http://www.who.int/mediacentre/ factsheets/fs094/en/
2. WHO, Antimalarial drug combination therapy: report of a technical consultation Geneva: World Health Organization 2001 http://whqlibdoc.who.int/hq/ 2001/WHO-CDS-RBM-2001.35.pdf
3. The clinical efficacy of artemether/lumefantrine (Coartem). Makanga M, Krudsood S, Malar J 2009 8 Suppl 1 5 10.1186/1475-2875-8-S1-S5
4. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Kokwaro G, Mwai L, Nzila A, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809 (Pubitemid 46070831)
5. Population pharmacokinetics and therapeutic response of CGP 56697(artemether + benflumetol) in malaria patients. Ezzet F, Mull R, Karbwang J, Br J Clin Pharmacol 1998 46 553 561 9862244 (Pubitemid 28522119)
6. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Lefevre G, Thomsen MS, Clin Drug Investig 1999 18 467 480 10.2165/00044011- 199918060-00006 (Pubitemid 30047534)
7. Coartem®: the journey to the clinic. Premji ZG, Malar J 2009 8 3
8. Safety profile of Coartem: the evidence base. Falade C, Manyando C, Malar J 2009 8 6
9. Artemether-lumefantrine full prescribing information. [ http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/ coartem.pdf ]
10. An integrated assessment of the clinical safety of artemether- lumefantrine: a new oral fixed-dose combination antimalarial drug. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E, Trans R Soc Trop Med Hyg 2000 94 419 424 10.1016/S0035-9203(00)90126-3 11127248 (Pubitemid 30662353)
11. Cochrane bias method group, Assessing risk of bias in included studies http://bmg.cochrane.org/assessing-risk-bias-included-studies
12. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. de Vries TW, van Roon EN, Arch Dis Child 2010 95 1023 1026 10.1136/adc.2009.175562 20551194
13. Understanding interobserver agreement: the kappa statistic. Viera AJ, Garrett JM, Fam Med 2005 37 360 363 15883903 (Pubitemid 40656185)
14. Meta-analysis in clinical trials. DerSimonian R, Laird N, Contr Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 (Pubitemid 17189972)
15. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, Clin Infect Dis 2009 49 1629 1637 10.1086/647946 19877969
16. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U, PLoS One 2009 4 7871 10.1371/journal.pone.0007871 19936217
17. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, PLoS Clin Trials 2007 2 20 10.1371/journal.pctr. 0020020 17525792 (Pubitemid 46860146)
18. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, Sandison TG, Homsy J, Tappero JW, Kamya MR, Dorsey G, Malar J 2009 8 272 10.1186/1475-2875-8-272 19948038
19. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H, PLoS One 2008 3 2390 10.1371/journal.pone.0002390 18545692
20. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. Four Artemisinin-Based Combinations (4ABC) Study Group, PLoS Med 2011 8 1001119 10.1371/journal.pmed.1001119 22087077
21. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, Ouédraogo JB, Clin Infect Dis 2007 45 1453 1461 10.1086/522985 17990228 (Pubitemid 351411875)
22. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U, Malar J 2011 10 50 10.1186/1475-2875-10-50 21352609
23. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tappero J, Kamya MR, Dorsey G, Sandison TG, Am J Trop Med Hyg 2010 83 873 875 10.4269/ajtmh.2010.10-0158 20889882
24. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, Kager PA, Malar J 2008 7 237 10.1186/1475-2875-7-237 19017387
25. A trial of combination antimalarial therapies in children from Papua New Guinea. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM, N Engl J Med 2008 359 2545 2557 10.1056/NEJMoa0804915 19064624
26. An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D, PLoS One 2008 3 2530 10.1371/journal.pone.0002530 18575626
27. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ, Malar J 2008 7 127 10.1186/1475-2875-7-127 18620577 (Pubitemid 352033070)
28. Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, Oduola AM, Happi CT, Malar J 2010 9 335 10.1186/1475-2875-9-335 21092220
29. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houzé P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P, J Infect Dis 2009 200 57 65 10.1086/599378 19469703
30. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, Nielsen MV, Vohwinkel J, Hogan B, Kreuels B, Bührlen M, Loag W, Ansong D, May J, Malar J 2008 7 261 10.1186/1475-2875-7-261 19099594
31. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG, Malar J 2008 7 106 10.1186/1475-2875-7- 106 18547415 (Pubitemid 351904896)
32. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG, PLoS Clin Trials 2006 1 7 10.1371/journal.pctr.0010007 16871329
33. High efficacy of two artemisinin-based combinations (artemether- lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM, Trop Med Int Health 2008 13 635 643 10.1111/j.1365-3156.2008.02043.x 18346028 (Pubitemid 351561605)
34. Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OA, Michael OS, Adewoye EO, Am J Trop Med Hyg 2011 84 813 819 10.4269/ajtmh.2011.10-0582 21540395
35. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ, Lancet 2005 365 1474 1480 10.1016/S0140-6736(05)66417-3 15850631 (Pubitemid 40591692)
36. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A, Clin Infect Dis 2005 41 1079 1106 10.1086/444460 16163624 (Pubitemid 41429468)
37. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, Ezedinachi E, Malar J 2006 5 43 10.1186/1475-2875-5-43 16704735 (Pubitemid 43865102)
38. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemdé R, Greenwood B, Ward SA, Winstanley PA, PLoS One 2009 4 6682 10.1371/journal.pone.0006682 19690618
39. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua kouté, Côte d'Ivoire. Toure OA, Kouame MG, Didier YJ, Berenger AA, Djerea K, Genevieve GO, Penali LK, Trop Med Int Health 2011 16 290 297 10.1111/j.1365-3156.2010.02701.x 21214690
40. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Faye B, Ndiaye JL, Tine R, Sylla K, Gueye A, Lô AC, Gaye O, Am J Trop Med Hyg 2010 82 140 144 10.4269/ajtmh.2010.09-0265 20065010
41. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, Mapunda E, Manjurano A, Amos B, Reyburn H, Whitty CJ, Clin Infect Dis 2009 49 1195 1201 10.1086/605635 19769536
42. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI, Am J Trop Med Hyg 2006 74 991 998 16760509 (Pubitemid 351627405)
43. Update on GSK's malaria treatments, Dacart and Lapdap http://www.gsk.com/media/press-releases/2008/update-on-gsks-malaria-treatments- dacart-and-lapdap.html
44. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI, PLoS Med 2012 9 1001339 10.1371/journal.pmed.1001339 23152723
45. Clinical and laboratory parameters in dapsone acute intoxication. Carrazza MZ, Carrazza FR, Oga S, Rev Saude Publica 2000 34 396 401 10.1590/S0034-89102000000400013 10973160
46. Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. Van Malderen C, Van Geertruyden JP, Machevo S, González R, Bassat Q, Talisuna A, Yeka A, Nabasumba C, Piola P, Daniel A, Turyakira E, Forret P, Van Overmeir C, van Loen H, Robert A, D' Alessandro U, Malar J 2012 11 139 10.1186/1475-2875-11-139 22546009
47. FDA clears genetic lab test for warfarin Sensitivity http://www.fda.gov/ newsevents/newsroom/pressannouncements/2007/ucm108984.htm
48. FDA approves Erbitux for colorectal cancer http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2004/ucm108244.htm
49. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Mayxay M, Khanthavong M, Lindegårdh N, Keola S, Barends M, Pongvongsa T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton PN, Clin Infect Dis 2004 39 1139 1147 10.1086/424512 15486837 (Pubitemid 40169311)
50. Use of mefloquine in children-a review of dosage, pharmacokinetics and tolerability data. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG, Malar J 2011 10 292 10.1186/1475-2875-10-292 21981927
51. Lariam (mefloquine hydrochloride) 250 mg tablets: Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 2009 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm181182.htm
52. Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria. Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, Oguche S, Ezeiru VI, Aina OO, Malar J 2008 7 172 10.1186/1475-2875-7-172 18782445
53. A systematic review of safety monitoring and drug toxicity in published randomized controlled trials of antiepileptic drugs in children over a 10-year period. Anderson M, Choonara I, Arch Dis Child 2011 95 731 738